Metsera, Inc./$MTSR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Metsera, Inc.
Metsera Inc is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight, and related conditions. The Company has developed and is implementing proprietary methods and platform technologies to advance a broad, scalable, and combinable portfolio of injectable and oral NuSH analog peptides with the potential to address not only the limitations of approved therapies but also many of the anticipated limitations of next-generation therapies in development. The Company uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization half-life extending platform.
Ticker
$MTSR
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
96
ISIN
US59267L1070
Website
Metsera, Inc. Metrics
BasicAdvanced
$3B
-
-$8.99
-
-
Price and volume
Market cap
$3B
52-week high
$37.99
52-week low
$12.30
Average daily volume
1.1M
Financial strength
Current ratio
6.554
Quick ratio
6.484
Long term debt to equity
0.102
Total debt to equity
1.925
Interest coverage (TTM)
-550.04%
Profitability
EBITDA (TTM)
-178.196
Effective tax rate (TTM)
3.29%
Management effectiveness
Valuation
Price to book
5.96
Price to tangible book (TTM)
7.3
Price to free cash flow (TTM)
-6.123
Free cash flow yield (TTM)
-16.33%
Free cash flow per share (TTM)
-468.91%
Growth
Bulls say / Bears say
Metsera's successful IPO raised $316.2 million, providing substantial capital to advance its pipeline of obesity treatments. (gurufocus.com)
Analysts from Guggenheim and BofA Securities have initiated coverage with 'Buy' ratings, indicating strong confidence in Metsera's growth potential. (defenseworld.net)
Metsera's lead candidate, MET-097i, demonstrated an average weight loss of 11.3% in a mid-stage trial, positioning it competitively in the obesity treatment market. (tradingview.com)
Metsera reported a Q4 net loss of $52.87 million, significantly widening from the previous year's loss, raising concerns about financial sustainability. (rttnews.com)
InvestingPro identified Metsera as significantly overvalued in March 2025, and the stock subsequently declined by 44%, reflecting market concerns about its valuation. (investing.com)
Metsera's operating expenses rose to $64.5 million in Q4, indicating increased spending that may impact profitability. (marketscreener.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.
Metsera, Inc. News
AllArticlesVideos
Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewsWire·3 weeks ago
Metsera Stock Rises As Company Advances Obesity Pipeline With Encouraging Weight Loss Data
Benzinga·3 weeks ago
Metsera rises as experimental weight-loss drug shows promise in small early-stage trial
Reuters·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Metsera, Inc. stock?
Metsera, Inc. (MTSR) has a market cap of $3B as of June 28, 2025.
What is the P/E ratio for Metsera, Inc. stock?
The price to earnings (P/E) ratio for Metsera, Inc. (MTSR) stock is 0 as of June 28, 2025.
Does Metsera, Inc. stock pay dividends?
No, Metsera, Inc. (MTSR) stock does not pay dividends to its shareholders as of June 28, 2025.
When is the next Metsera, Inc. dividend payment date?
Metsera, Inc. (MTSR) stock does not pay dividends to its shareholders.
What is the beta indicator for Metsera, Inc.?
Metsera, Inc. (MTSR) does not currently have a Beta indicator.